BCL-2 family proteins and cellular bioenergetics in the control of cell survival: Towards novel predictive and prognostic markers for disease progression and therapy responses in colorectal cancer patients

Cancer has the most devastating economic impact (~$895 billion) of any cause of death, with many countries losing more than 1% of their GDP to the disease. Bowel cancer is the third most common cancer, and patients frequently receive but more often fail to respond to chemotherapy. Our  research programme will identify and develop tests that indicate to physicians the patients that are likely to benefit from chemotherapy, and the best treatment options for those individual patients. The tests developed will also open new opportunities for indigenous industry and may help reduce health care costs by avoiding unnecessary chemotherapy.

This project is funded by SFI.